Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality

NCT02034279 is registered in ClinicalTrials.gov with EASL - CLIF Consortium as lead sponsor.

NCT NCT02034279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02034279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality
Lead sponsor
EASL - CLIF Consortium
Phase
Phase 4
Overall status
Terminated
Start date
May 31, 2014
Completion date
February 10, 2017
Enrollment
136 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced chronic liver disease, cholangitis, other bacterial diseases, pneumonia, urinary infection